Tweet
Nat Commun
. 2020 Jul 14;11(1):3518.
doi: 10.1038/s41467-020-17189-2.
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
Sepideh Sadegh 1 , Julian Matschinske 1 , David B Blumenthal 1 , Gihanna Galindez 1 , Tim Kacprowski 1 , Markus List 1 , Reza Nasirigerdeh 1 , Mhaned Oubounyt 1 , Andreas Pichlmair 2 , Tim Daniel Rose 3 , Marisol Salgado-Albarr?n 1 4 , Julian Sp?th 1 , Alexey Stukalov 2 , Nina K Wenke 1 , Kevin Yuan 1 , Josch K Pauling 3 , Jan Baumbach 5 6
Affiliations
- PMID: 32665542
- DOI: 10.1038/s41467-020-17189-2
Abstract
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.